Archive for Декабрь, 2008
Will FDA Advisory Committee Consider Acomplia, and When?
The U.S. Food and Drug Administration advisory committee that is expected to weigh in on the new anti–obesity drug Acomplia (rimonabent) prior to an FDA decision on approval apparently does not intend to take up the drug at its December meeting.
The FDA’s Endocrinologic and Metabolic Drugs Advisory [...]
UK Company Plans Trial of Diet Drug With Same Target as Acomplia (Rimonabant)
GW Pharmaceuticals Acomplia (rimonabant) , a U.K. company with an announced goal of being the global leader in prescription cannabinoid medicine, said on Jan. 30 it hopes to soon start a Phase I clinical trial of an experimental diet drug derived from cannabis.
The company said researchers [...]
2d Generic Version of Diet Pill Rimonabant (Acomplia / Zimulti) Launched in India
ond Acomplia (rimonabant) Indian pharmaceutical company, Torrent Pharmaceuticals Ltd., has announced that it also is selling a generic version of the new Sanofi-Aventis diet drug Acomplia (rimonabant) under the name Rimoslim.
The news, which attracted little attention in the West, occurred almost simultaneously with last week’s announcement by Zydus [...]
A year ago at this time, millions of overweight and obese Americans were excitedly awaiting both a new prescription weight-loss drug, rimonabant (Acomplia / Zimulti) , and the first over-the-counter diet drug, Alli (low-dose Xenical), which were expected to be on the U.S. market by [...]
